Navigation Links
Angiotech Pharmaceuticals Announces Conference Call and Webcast
Date:6/24/2010

Second Quarter 2010 Financial Results

VANCOUVER, June 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the second quarter ended June 30, 2010, on Friday, July 30, 2010 at 11:00 AM ET (8:00 AM PT).

Dial-in information for the earnings call on July 30, 2010 is as follows:

    North America (toll-free): (866) 277-1182
    International: (617) 597-5359
    Enter Passcode: 18173223

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investors section.

A press release announcing Angiotech's financial results will be issued prior to the call on July 30th at approximately 8:00 AM ET (5:00 AM PT).

An archived replay of the call will be available until August 6, 2010.

Replay information is as follows:

    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 33507758

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
2. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
3. Angiotech Pharmaceuticals Announces Conference Call and Webcast
4. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
10. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
11. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- --> --> Q ... to provide the following update on recent corporate developments. ... 3 months we have significantly increased our cash position through ... a result, we have positioned ourselves to execute on the ... expect that development to continue on schedule. ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... supplier of Semantic Graph Database technology has been recognized As “ Best in ... Corporate America Magazine. , “At Corporate America, it’s our priority to showcase prominent ...
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):